Summary
In this study, 17 women were treated for uncomplicated acute pelvic inflammatory disease requiring hospitalisation for therapy, and 5 women were treated for the same infection complicated by pelvic abscesses. Treatment regimens were sulbactam 1g plus ampicillin 2g (14 women) or cefoxitin 2g (8 women) given by intravenous infusion every 6 hours. On the third day of therapy, a rash developed in 1 woman who was being successfully treated for uncomplicated disease with sulbactam/ampicillin. The other 21 women were cured. No other adverse clinical reactions and no significant abnormal laboratory results were observed with either regimen. Bacteriological efficacy, 98% for sulbactam/ ampicillin and 94% for cefoxitin, closely paralleled clinical efficacy. Sulbactam, a suicidetype β- lactamase inhibitor, appears to have restored and expanded the antibacterial activity of ampicillin.
Similar content being viewed by others
References
Rrunham RC. Therapy for acute pelvic inflammatory disease: a critique of recent treatment trials. American Journal of Obstetrics and Gynecology 148: 235–240. 1984
Hadgu A. Westrom L. Brooks CA. Reynolds GH. Thompson SE. Predicting acute pelvic inflammatory disease: a multivariate analysis. Obstetrics and Gynecology 155: 954–960. 1986
Hager WD, Eschenbach DA, Spence MR. Sweet RL. Criteria for diagnosis and grading of salpingitis. Obstetrics and Gynecology 61: 113–114, 1983
Hemsell DL. Sulbactam/ampicillin for treatment of polymicrobial pelvic infections. Drugs 31 (Suppl. 2): 22–25. 1986
Stamm WE, Holmes KK. Measures to control Chlamydia trachomatis infections: an assessment of new national policy guidelines. Journal of the American Medical Association 256: 1178–1179, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hemsell, D.L., Heard, M.C., Hemsell, P.G. et al. Sulbactam/Ampicillin versus Cefoxitin for Uncomplicated and Complicated Acute Pelvic Inflammatory Disease. Drugs 35 (Suppl 7), 39–42 (1988). https://doi.org/10.2165/00003495-198800357-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198800357-00010